Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Eli Lilly said its drugs showed no signs of live injury in the trial. This is welcome news for researchers after Pfizer ...

A good safety profile and signs of efficacy as a weight-loss treatment suggest orforglipron ... is that you don't have to wait for soaring GLP-1 sales. Tirzepatide was first approved as a diabetes ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

“Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be sustained for up to 3 years in a diverse population of adults with overweight or obesity but not ...

Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S.